ASCO GU 2015: Prostate highlights from day one

Metastatic prostate cancer - Interpreting negative trial results

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

Expert commentary on emerging research in genitourinary cancer

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

Impact of statins on survival outcomes in metastatic renal cell carcinoma

Genomic profiling may reveal new drug targets in urothelial carcinoma

Taxane response in prostate cancer may not be influenced by androgen receptor variations

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Effectiveness of adjuvant chemotherapy on patients with bladder cancer

New approach to prostate cancer screening

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer

When and whether to conduct endocrine therapy in non-metastatic prostate cancer

Combination of pazopanib and paclitaxel safe in urothelial cancer

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer?